Research Progress on the Effect of NLRP3 Inflammasome on Myocardial Fibrosis and Drug Intervention
Abstract
characterized by the accumulation of extracellular matrix in the myocardium, which leads to arrhythmia and impaired cardiac function, and
eventually to heart failure. However, there is currently no specific clinical treatment to reverse or delay the progression of cardiac fibrosis. Nucleotide-binding oligomerized domand-like receptor protein 3 (NLRP3) inflammasome is a protein complex that is activated by endogenous
and exogenous signals and is involved in the development and progression of a variety of diseases. In recent years, studies have shown that
the abnormal activation of NLRP3 inflammasome is closely related to the occurrence and development of myocardial fibrosis. As a potential
target for the treatment of myocardial fibrosis, the NLRP3 inflammasome is expected to provide a new strategy and direction for the treatment
of myocardial fibrosis by inhibiting its overactivation. This paper aims to systematically review the impact of the NLRP3 inflammasome on
myocardial fibrosis and to explore advancements in its treatment strategies.
Keywords
Full Text:
PDFReferences
[1] Gonzalez A, Schelbert E B, Diez J, et al. Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives[J]. J
Am Coll Cardiol, 2018, 71(15): 1696-1706.
[2] Coll R C, Hill J R, Day C J, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition[J]. Nat Chem
Biol, 2019, 15(6): 556-559.
[3] Menu P, Vince J E. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly[J]. Clin Exp Immunol, 2011,
166(1): 1-15.
[4] Bauernfeind F G, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license
NLRP3 inflammasome activation by regulating NLRP3 expression[J]. J Immunol, 2009, 183(2): 787-791.
[5] Mulay S R. Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases[J]. Kidney Int,
2019, 96(1): 58-66.
[6] Pinar A A, Scott T E, Huuskes B M, et al. Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis[J]. Pharmacol Ther, 2020,
209: 107511.
[7] Wynn T A, Vannella K M. Macrophages in Tissue Repair, Regeneration, and Fibrosis[J]. Immunity, 2016, 44(3): 450-462.
[8] Pellicoro A, Ramachandran P, Iredale J P, et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ[J]. Nat
Rev Immunol, 2014, 14(3): 181-194.
[9] Gao R, Shi H, Chang S, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac
remodeling in a mouse model of myocardial infarction[J]. Int Immunopharmacol, 2019, 74: 105575.
[10] Liu Yan, Liu Mengnan, Yang Tingfu, et al. The effect of Hilong Huoxuetongyu capsule on hypertensive myocardial fibrosis by regulating NLRP3 signaling pathway %J Pharmacology and Clinic of Traditional Chinese Medicine [J], 2024, 40(05): 23-30.
[11] Li R, Lu K, Wang Y, et al. Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3
inflammasome expression[J]. Biochem Biophys Res Commun, 2017, 485(1): 69-75.
[12] Lu B, Xie J, Fu D, et al. Huoxue Qianyang Qutan recipe attenuates cardiac fibrosis by inhibiting the NLRP3 inflammasome signalling
pathway in obese hypertensive rats[J]. Pharm Biol, 2021, 59(1): 1045-1057.
[13] Sandanger O, Ranheim T, Vinge L E, et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial
ischaemia-reperfusion injury[J]. Cardiovasc Res, 2013, 99(1): 164-174.
[14] Liu W, Sun J, Guo Y, et al. Calhex231 ameliorates myocardial fibrosis post myocardial infarction in rats through the autophagy-NLRP3
inflammasome pathway in macrophages[J]. J Cell Mol Med, 2020, 24(22): 13440-13453.
DOI: http://dx.doi.org/10.70711/pmr.v2i4.6108
Refbacks
- There are currently no refbacks.
